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Introduction
　In Japan, historically, doctors had refrained from disclosing a cancer diagnosis to patients. 
Nevertheless, this gradually began changing in the early 1990’s due mainly to the growing 
importance of informed consent.  Apart from the expected and normal emotional impact, 
learning about their diagnosis has allowed patients to participate in decision-making concern-
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Furthermore, we noted that anxiety and depression were not detected after the 
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that anxiety and depression were alleviated by events such as surgery.  It is 
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ing their treatment. Doctors, on the other hand, have to keep in mind the psychological 
conditions of their patients after disclosing the diagnosis and have to express their sincere 
empathy to establish a caring physician-patient relationship1, 2）. Showing sympathy and 
providing appropriate counseling have helped patients to reduce their distress and facilitate 
psychological adjustment.
Materials and Methods
　In this study, the patient’s medical condition and timing for disclosure was revealed to 
his/her family and then to the patient.  Therefore, we told the patient about their cancer 
while they were accompanied by their family.  We described the whole procedure of total 
resection of the tumor to patients in stages I, II, III （cancer without distant metastases） and 
added an explanation regarding chemotherapy in the case of patients with stage IV cancer 
（cancer with distant metastases）.
　Thirty-seven cancer patients （7 with gastric cancer, 23 with colorectal cancer, 5 with breast 
cancer, and 2 with hepatocellular carcinoma）, who were operated on at Yamanashi Red 
Cross Hospital from September 2005 to August 2007, were informed of their state of cancer. 
The patients with breast cancer were told the diagnosis and were informed about the surgical 
procedure before the operation, and others were told the diagnosis after surgery （Table 1）.
　We evaluated the level of anxiety and depression of the patients using the Hospital Anxi-
ety and Depression Scale （HADS）3）.  HADS includes the points of anxiousness ［HADS
（A）］ and those of depression ［HADS（D）］.  This scale is useful to evaluate symptoms 
such as dejection or uneasiness by asking patients to answer 14 questions （dejection-related 
7 questions, uneasiness-related 7 questions）4, 5）.  If the points of HADS had were elevated, 
we would diagnose that degree of anxious/ depression was worsened.  Generally, the HADS
（D） points for dejection state was over nine points, or over 13 points in the case of HADS
（A） plus HADS（D） was defined as anxious/ depression state.  HADS was used once 
before the disclosure of the cancer diagnosis, and 5 times （Weeks 1, 3, 5, 7, 9） after diag-
nosis.  We divided the patients at Week 1 after disclosure into two groups : one group of 
patients whose HADS ［HADS（A） or HADS（D）］ points were 8 points or more （Group 
A）, and another group whose points were below 8 （Group B）.
　We prescribed paroxetine hydrochloride hydrate （PAX） to the patients in Group A.  Sig-
nicant differences between the two groups were assessed using the Mann-Whitney’s U test. 
The level of statistical signicance was set at p＜ 0.05.
Results
　There were 11 （29.7%） patients in Group A, and 26 （70.3%） in Group B （Table 1）.
　1. Comparison of Group A with Group B
　1）Background
　The average age of Group A was 67.7 years old, and that of Group B was 66.2 years 
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Table 1.  Clinical Data and groups. 
No. Age Gender Cancer stage
1 71 M HCC Ⅱ
group A
Effective Group
2 78 M Gastric Ca ⅠA
3 52 F Cecum Ca 0
4 71 M S/C Ca Ⅰ
5 80 M S/C Ca Ⅱ
6 64 M Rectum Ca Ⅲa
7 73 F Rectum Ca Ⅲa
8 67 F A/C Ca Ⅲb
9 68 F Gastric Ca ⅠA Ineffective Group
10 64 M Cecum Ca 0
11 57 F A/C Ca 　
1 77 M HCC Ⅲ
Group B
2 58 M Gastric Ca Ⅳ
3 57 M Gastric Ca ⅠA 
4 52 M Gastric Ca ⅠA 
5 80 F Gastric Ca Ⅲa
6 90 M Gastric Ca ⅢA
7 89 M Rectum Ca 0
8 42 F S/C Ca 0
9 65 M S/C Ca 0
10 69 M Rectum Ca Ⅰ
11 68 M S/C Ca Ⅰ
12 73 M Rectum Ca Ⅱ
13 52 M D/C Ca Ⅱ
14 75 M Rectum Ca Ⅱ
15 72 M Rectum Ca Ⅱ
16 79 M S/C Ca Ⅲa
17 72 M D/C Ca Ⅲa
18 71 F S/C Ca Ⅲa
19 49 F S/C Ca Ⅲa
20 73 M S/C Ca Ⅲa
21 66 F Cecum Ca Ⅳ
22 46 F Breast Ca ⅡA
23 80 F Breast Ca ⅢA
24 60 F Breast Ca ⅡA
25 37 F Breast Ca ⅡB
26 71 F Breast Ca ⅡA
M : Male, F : Female, HCC : hepatocellular carcinoma, Cecum Ca : cecum cancer, A/C 
Ca : ascending colon cancer, D/C Ca : descending colon cancer, S/C Ca : sigmoid colon 
cancer, Rectum Ca : rectum cancer, Gastric Ca : gastric cancer, Breast Ca : breast cancer
The patients with breast cancer were told the diagnosis and were informed about 
the surgical procedure before the operation, and others were told the diagnosis after 
surgery. 
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old, showing no signicant difference between the two groups.  The male to female ratio 
was 7 : 4 in Group A, and 16 : 10 in Group B.  There was no statistical difference between 
the two groups regarding these items.
　2）Median Score of HADS
　The median points of HADS in Group A and Group B are shown in Table 1 and Fig. 
1.  There were differences between both groups before disclosure of the diagnosis of cancer, 
and at Weeks 3 and 5 after disclosure.  There was no difference in the average points of 
HADS at Weeks 7 and 9.
　There was no difference between points of HADS（A） and that of HADS（D） before 
disclosure in Group A ［HADS（A）: 5 cases, HADS（D）: 6 cases］.  Before disclosure, the 
points of HADS in Group A was signicantly higher than that in Group B.
　On the other hand, there the low points of HADS were maintained throughout Weeks 3, 
5, 7, 9 in Group B.
　We examined whether HADS（A） and HADS（D） inuenced HADS in Group A and 
B.  But there was no statistical difference between the inuence of HADS（A） and that of 
HADS（D）.
Fig. 1.  Comparison of Group A with Group B
Group A : Cases with HADS ［HADS（A） or HADS（D）］ points of 8 points or more. Group B : 
Cases with HADS ［HADS（A） or HADS（D）］ points of below 8 points. There were differences 
between both groups before disclosure of the diagnosis of cancer, and at Weeks 3 and 5 after 
disclosure. There was no difference in the average points of HADS at Weeks 7 and 9.
HADS（A）
HADS（D）
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　3） Ratio of patients that received treatment after disclosure of the diagnosis of colorectal, 
gastric, and breast cancers.
　There were many cases with these types of cancers.  The ratio of patients with a HADS 
of 8 or more in each cancer （Table 2） was 34.7% of patients with colorectal cancer, 28.6% 
of those with gastric cancer, and 0% of patients with breast cancer.
　2.  Investigation in Group A subdivided into an effective subgroup and an ineffective sub-
group by their response to PAX
Fig. 2.   Comparison of the Effective Subgroup ［Group A（E）］ with the Ineffective Subgroup of 
Group A ［Group A（I）］ Group B : Cases with HADS ［HADS（A） or HADS（D）］points 
of below 8. Eight （72.7%） of the 11 patients in the Group A（E） showed an improvement 
of anxiety or depression by Week 5.
Table 2.   Ratio of patients treated with PAX after disclosure of the 
diagnosis of colorectal, gastric, and breast cancers. About 
30% of patients in colorectal and gastric cancer needed 
medication. But the patients of breast cancer did not 
need to treatment.
Group A vs. Group B Raito of Treatment
Colorectal Cancer 8 15 34.7%
Gastric Cancer 2 5 28.6%
Breast Cancer 0 5 0.0%
HADS（A）
HADS（D）
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　1）Effective Group ［Group A（E）］ vs. Ineffective Group［Group A（I）］
　The effective subgroup ［Group A（E）］ included patients who scored 8 points or more 
in HADS, had taken PAX since Week 1 after disclosure and then showed an improvement 
of anxiety and depression （HADS points below 8） by Week 9 after disclosure.  Ineffective 
cases was dened as the ineffective subgroup ［Group A（I）］.  Eight （72.7%） of the 11 
patients in Group A showed an improvement of anxiety or depression by Week 5 （Fig. 
2）.  When median score of HADS points was compared with Group A（E） and Group A
（I）, there was a difference between the two groups by Week 3, but it was not statistically 
signicant.
　As for the three patients in Group A（I）, one had gastric cancer （stage I）, another had 
cecum cancer （stage 0）, and the other had ascending colonic cancer （stage IV）（Table 1）. 
The woman with gastric cancer （stage I） suffered from loss of appetite after the operation. 
The patient with early cecum cancer worried about treatment for prostate cancer emerging 
after ileocecectomy.  And the one with ascending colonic cancer and liver metastasis （stage 
IV） was depressed because chemotherapy was not effective, and she had developed icterus 
（Table 1）.
　The ratio of success of therapy with PAX was independent of the cancer stage, suggesting 
that it was hard to obtain a response succeed when there was a negative physical factor 
present.
Discussion
　In recent years, as the possibilities of treatment for cancer have increased, not only tumor 
resection, but also neoadjuvant chemotherapy, adjuvant chemotherapy and radiotherapy 
are performed for patients.  Some patients suffer severe adverse effects of these therapies, 
and thus it has become necessary to disclose the diagnosis to them.  Consequently, clinical 
doctors must consider the mental care of patients after disclosure.  Massie and Holland 
proposed three phases of mental state in the patients 6）.  The initial period after disclosure, 
which usually lasts a few days, is characterized by disbelief or denial.  At rst, the patients 
are shocked, become dizzy, and show denial and despair.  Phase 2, which usually lasts 1-2 
weeks after phase 1, is characterized by dystopia, for example anxiety, anorexia, insomnia 
and poor concentration.  Phase 3 begins after Week 2, when patients start accepting the 
reality of their diagnosis.  The morbidity rate of depression after disclosure of a cancer diag-
nosis is 10-20% for all cancer stages, and the rate of anxiety and depression is considered 
to be 30-40% 7）.
　In this study, psychic uneasiness / dejection after disclosure of a cancer diagnosis was 
observed in 11 （29.7%） of the 37 patients, and accounted for 34.4% of the 32 patients who 
were informed of the diagnosis after the operation.  The cause of uneasiness was unknown, 
but there was no difference associated with the stage of cancer.  Moreover, it will be neces-
sary for specic the investigation of the uneasiness / dejection after disclosure of cancer 
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was performed for each organ.  In addition, the improvement of uneasiness / dejection with 
PAX became clear under the presence of a negative physical element.
　In addition, HADS points did not worsen in any breast cancer patient whose diagnosis 
was disclosed to them before the operation.  In these patients, an event such as the opera-
tion moderated the mental pain of the patient, and it seemed that, as a result, the points of 
HADS were low.  It seems necessary to examine this aspect in relation to cancer affecting 
other internal organs in the future.
　The patients whose HADS points increased after the disclosure already had a high point 
in HADS before the disclosure.  In other words, such a patient originally had a risk factor 
for anxiety and depression.  In addition, the effect of PAX was observed in about 1 month, 
because there was no difference in the HADS points between Group A and Group B at 
Weeks 7 and 9.  Furthermore, we examined whether anxiety or depression inuenced the 
HADS after disclosure.  Depression tended to affect the mental condition of the patient at 
Weeks 3 and 5 7-9）.
　We noted that anxiety and depression after the disclosure was not detected in any of the 
breast cancer patients in Group B.  Therefore, the possibility that anxiety and depression 
were alleviated, at least in part, by events such as surgery was suggested.
　It is necessary for medical treatment to advance to new steps in the treatment of cancer, 
providing enough support to the patients in the future.
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